Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
- None.
- None.
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (鈥淩eviva鈥� or the 鈥淐ompany鈥�), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Format: Corporate update
Date/Time: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET for registered conference attendees
Location: Virtual
Registration Link:
About Reviva聽
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva鈥檚 current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva鈥檚 pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD聽
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the H.C. Wainwright Neuro Conference 2025?
Who will be presenting for Reviva Pharmaceuticals at the H.C. Wainwright conference?
What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?
Is the H.C. Wainwright Neuro Perspectives Conference 2025 virtual or in-person?
